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Poster Session II 115(n 5 10), NHL (n 5 7), Hodgkin’s lymphoma (n 5 6), advanced
CML (n5 4), and advanced CLL (n5 4). 9 pts had previously un-
dergone autografting. 80% received HLA-identical grafts. All pts
were conditioned with fludarabine (30 mg/m2/day, days -7 to -3),
busulfan (0.8 mg/kg/dose IV  8 doses) and rabbit ATG (2.5 mg/
kg/day, days -4 to -2) followed by micro-dose methotrexate and ta-
crolimus. Stem cell source included peripheral blood (n 5 26) or
bone marrow (n 5 4). All pts engrafted neutrophils and platelets
promptly (median 15 and 16 days, respectively). There were no pri-
mary graft failures. Rates of grade II-IV and III-IV aGVHD were
43% (n5 13) and 23% (n5 7) respectively. 9 pts (30%) developed
cGVHD but extensive cGVHD was seen in only 10% (n5 3). Day
100 TRM was 10% (n5 3). CMV and EBV reactivation occurred in
30% (n 5 9) and 20% (n 5 6) respectively. 2 pts developed PTLD
requiring rituximab. 3 pts had BK-virus associated hemorrhagic
cystitis. Chimerism analysis showed 100% donor CD331 at all
time points (days 30, 60, 100) and median donor CD31 chimerism
of 94% at day 130 and 100% at day 1100. One pt had secondary
graft failure. 23 pts (76%) were in CR after SCT. Kaplan-Meier es-
timates of overall survival (OS) and progression free survival (PFS)
at 1 year are 62% and 43% respectively. OS (P 5 0.95) and PFS (P
5 0.65) was not statistically significant between recipients of
matched and mismatched grafts. In conclusion, FBA and tacrolimus
based GVHD prophylaxis achieved rapid donor chimerism and a fa-
vorably low incidence of TRM and cGVHD despite being tested in
poor risk pts. However the rates of EBV reactivation and disease re-
lapse warrant further exploration of this approach using lower doses
of ATG (e.g. 5–6 mg/kg total dose).311
ALLOGENIC STEM CELL TRANSPLANTATION IN PATIENTS WITH AC-
QUIRED APLASTIC ANEMIA AND FANCONNI ANEMIA: A SINGLE CENTER
EXPERIENCE OVER 11 YEARS
Rosales, C., Abello, V., Esguerra, H.J., Pedraza, E., Linares, A.,
Rosales, M.L. Clınica de Marly, Bogota, Colombia.
We performed a retrospective analysis, of allogenic stem cell
transplantation (allo-SCT) results, in 40 patients with diagnosis of
acquired aplastic anemia or Fanconni Anemia, in a transplant center
in Bogota, Colombia, between 1996 and 2007.
During that period, 42 transplants were performed in 40 patients.
28 (70%) acquired aplastic anemia and 12 (30%) Fanconni’s Ane-
mia. 17 (42.5%) female/25 (62.5%) male. Mean age was 22 years
(4–57).
Stem cells were obtained from peripheral blood in 36 (90%) and
from bone marrow in 6 (15%). The majority of patients were of
high risk; the mean time from diagnosis to transplant was 27.8 months
(2–141) and 57.5% of them had received more than 20 transfusions
before transplantation. Patients were conditioned with Cy-ATG in
24 (57.1%), high dose Cyclophosphamide (Cy) in 11 (26.2%), fludar-
abine-Cy-ATG in 3 (7.14%) and Alemtuzumab-Cy in 4 (9.52%).
Mean CD341 cell dose was 3.3 (1.08–6.66), TNC: 9.7 (1.2–
59.2).
Neutrophil engraftment was achieved at day 116 (3–54) post-
transplantation.
At a mean follow up of 19.5 months (7–128), overall survival is
65%.
Comparison of results of different conditioning regimens shows
that overall survival for patients conditioned with Cy alone is disap-
pointing, 8/11 patients died, 6 due to GVHD and 2 due to infection.
After adding ATG to Cy, mortality due to GVHD was significantly
reduced. Only 7/24 patients died, GVHD was the cause of death
only in 2. Infection was the cause of death in other 4. 2 patients
had secondary graft failure, one died. The other received a second
transplant and is alive with mixed chimerism, but free of transfusion
support.
Of 4 patients treated with alemtuzumab containing regimens, 3
had secondary graft failure, 2 died, and one received a second trans-
plant successfully.
On this group of patients Cy-ATG was the best conditioning reg-
imen in terms of overall survival and GVHD incidence. The major-
ity of patients in this cohort were remitted to transplant late in their
disease, early treatment will probably improve the outcomes, as it
has been confirmed in other papers.312
DOG LEUKOCYTE ANTIGEN (DLA)-IDENTICAL SIBLING CORD BLOOD
TRANSPLANTATION (CBT) FOLLOWING MYELOABLATIVE TOTAL
BODY IRRADIATION (TBI)
Lesnikov, V.1, Baran, S.1, Abrams, K.1, Zellmer, S.1, Yang, Y.-J.1,
Heimfeld, S.1, Lesnikova, M.1, Nash, R.A.1,2, Georges, G.E.1,2. 1Fred
Hutchinson Cancer Research Center, Seattle, WA; 2University of
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Cord blood (CB) is increasingly used for hematopoietic cell
transplantation due to its rapid availability and less stringent HLA
matching requirements. However, low cell dose of CB units and de-
layed engraftment remain significant obstacles for increased use of
CBT in adults. We aim to develop a large animal model of CBT
by using outbred dogs to improve the understanding of engraftment
across histocompatibility barriers and cell dose limitations of CBT.
We harvested and cryopreserved individual units of canine CB ob-
tained from litters following Caesarian section at day 54 to 60 of
gestation. We asked if single or multiple units of DLA-identical sib-
ling CB could engraft in DLA-identical recipient dogs. Eight adult
dogs received 920 cGy TBI followed by intravenous infusion of
thawed CB, either a single CB unit (n 5 3) or multiple [2 to 4]
CB units (n 5 5) with a combined total nucleated cell (TNC)
dose range 0.3–2.6  107/kg. Transplanted total CD341 cell dose
was 0.2–2.5  105/kg. Postgrafting immunosuppression was cyclo-
sporine 1 mycophenolate mofetil for 35 and 28 days, respectively.
G-CSF was given until recovery of neutrophil counts. Three dogs
died on days 13–17 due to neutropenic sepsis. Five dogs engrafted
and survived; and are currently 265–621 days after CBT. Sustained
neutrophil recovery.1000/mL occurred 29–35 days after CBT, and
platelet recovery .20,000/mL was 38–84 days after CBT. Monthly
chimerism analysis was assessed by PCR using informative microsa-
tellite markers. Among each of the 4 surviving recipients of multiple
unit CBT, all transplanted donor CB units contributed to hemato-
poiesis with sustained multi-donor chimerism. However, in all 4
dogs, 1 of the CB units eventually dominated hematopoiesis with
sustained 75–95% donor chimerism. In all cases the dominant CB
unit had the highest TNC dose. There was no acute or chronic
GVHD. From 3–8 months after CBT, immune reconstitution stud-
ies normalized including T cell proliferation allo-stimulation index,
1o and 2o immune response to sheep red blood cells and recovery of
the absolute number of CD4 and CD8 T-cell subsets. In summary,
cryopreserved DLA-identical CB successfully engrafted and pro-
vided durable hematopoietic recovery. There was stable multi-do-
nor chimerism and the CB unit with the greatest TNC dose
predicted the dominant donor graft. The approximate minimum
cell dose threshold for successful engraftment of a single CB unit
with this conditioning regimen model was 0.8  107 TNC/kg.313
TACROLIMUS DOSING IN ALLOGENEIC HEMATOPOIETIC STEM-CELL
TRANSPLANTATION RECIPIENTS RECEIVING VORICONAZOLE
Trifilio, S.M., Pi, J., Singhal, S., Frankfurt, O., Evens, A., Gordon, L.,
Tallman,M.,Winter, J., Williams, S., Mehta, J. Northwestern Univer-
sity, Chicago.
Tacrolimus (TAC) is primarily metabolized by the CYP450 3A4
isoenzyme. Voriconazole, often used to prevent fungal infections af-
ter allogeneic HSCT, is metabolized by the CYP450 3A4, 2C9 and
2C19 isosenzymes. Clinical trials in healthy volunteers have shown
significant drug interactions between the two requiring TAC dose
reduction. Ordinarily, TAC is started at the dose of 0.03 mg/kg
IV daily on day -1. After starting it at this dose and having to reduce
the dose substantially within 2–3 days in all patients receiving con-
comitant voriconazole 200 mg twice daily orally from day 0, we im-
plemented a simple, preemptive TAC dose reduction strategy to
maintain steady-state levels between 5 and 15 ng/mL. As a first
step, IV TAC was initiated at the reduced dose of 0.022 mg/kg/
day. As a second step, dose was reduced by 30–40% if the steady-
state level 48 h after initiation of TAC (day 11) was between 7
and 10 ng/mL, and by 40–50% if the level was between 10 and 15
ng/mL. No change was made if the level was\7 ng/mL. Subse-
quently, levels were monitored 2–3 times a week and the dose
